JP2024536862A - Ｉｌ－１７の調節因子としてのベンズイミダゾール - Google Patents

Ｉｌ－１７の調節因子としてのベンズイミダゾール Download PDF

Info

Publication number
JP2024536862A
JP2024536862A JP2024518802A JP2024518802A JP2024536862A JP 2024536862 A JP2024536862 A JP 2024536862A JP 2024518802 A JP2024518802 A JP 2024518802A JP 2024518802 A JP2024518802 A JP 2024518802A JP 2024536862 A JP2024536862 A JP 2024536862A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
pharma
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518802A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023049888A5 (https=
JP2024536862A5 (https=
Inventor
デクハット，シャーロット，プーリー
ベーナ，ダグラス，シー．
ベンベネック，スコット
ゴールドバーグ，スティーブン，ディー．
ジャクソン，ポール，エフ．
キース，ジョン
ロスコット，スティーブン，エイ．
マーティン，コナー
マクカーヴァー，ステファン
メドゥナ，スティーヴン，ピー．
ローラー，ティモシー，ビー．
シー，エイミー，ワイ．
タニス，ヴァージニア，エム．
ウッズ，クレイグ，アール．
シュエ，シャオフア
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2024536862A publication Critical patent/JP2024536862A/ja
Publication of JPWO2023049888A5 publication Critical patent/JPWO2023049888A5/ja
Publication of JP2024536862A5 publication Critical patent/JP2024536862A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024518802A 2021-09-27 2022-09-26 Ｉｌ－１７の調節因子としてのベンズイミダゾール Pending JP2024536862A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163248569P 2021-09-27 2021-09-27
US63/248,569 2021-09-27
PCT/US2022/077003 WO2023049888A1 (en) 2021-09-27 2022-09-26 Benzimidazoles as modulators of il-17

Publications (3)

Publication Number Publication Date
JP2024536862A true JP2024536862A (ja) 2024-10-08
JPWO2023049888A5 JPWO2023049888A5 (https=) 2025-10-01
JP2024536862A5 JP2024536862A5 (https=) 2025-10-01

Family

ID=83880137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518802A Pending JP2024536862A (ja) 2021-09-27 2022-09-26 Ｉｌ－１７の調節因子としてのベンズイミダゾール

Country Status (6)

Country Link
US (1) US20240376085A1 (https=)
EP (1) EP4408530A1 (https=)
JP (1) JP2024536862A (https=)
CN (1) CN118119613A (https=)
CA (1) CA3233410A1 (https=)
WO (1) WO2023049888A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
WO2025247285A1 (zh) * 2024-05-28 2025-12-04 西藏海思科制药有限公司 一种可抑制il-17a的杂环化合物制备及其用途
WO2026012492A1 (en) * 2024-07-12 2026-01-15 Anew Therapeutics Pte. Ltd. Heterocyclic compounds as il-17 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019138017A1 (en) * 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators
WO2019223718A1 (zh) * 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂

Also Published As

Publication number Publication date
EP4408530A1 (en) 2024-08-07
CA3233410A1 (en) 2023-03-30
CN118119613A (zh) 2024-05-31
US20240376085A1 (en) 2024-11-14
WO2023049888A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
JP7664947B2 (ja) Ｉｌ－１７の調節因子としてのイミダゾリダジン
AU2018217860B2 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
AU2012245106B2 (en) Androgen receptor modulating carboxamides
TW201944993A (zh) Ｃｂｌ-ｂ抑制劑及其使用方法
JP2024536862A (ja) Ｉｌ－１７の調節因子としてのベンズイミダゾール
KR20180103158A (ko) 피라졸로[1,5-a]피라진-4-일 유도체
JP2022550297A (ja) Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のヘテロ多環式モジュレーター
JP2016540811A (ja) Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
JP2023548169A (ja) 統合的ストレス経路の調節剤
EP4408837A1 (en) Benzimidazole and azabenzimidazole il-17 inhibitor compounds
WO2014157382A1 (ja) スフィンゴシンキナーゼ阻害剤
EA049631B1 (ru) Имидазопиридазины в качестве модуляторов il-17
JP2025536386A (ja) モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害剤としての複素環式化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250922